Member Info for JungleVIP

...any minute. Well done those wiring this crazy wave. L2 looking VERY strong. GL

Its a public forum Davey. Seriously mate, come on!!

£300 is good right now in today's market. Good on them. A little patience though, would see a lot more in their pocket. Imo....of course

GL

Took some for a punt this morning. But research shows a little patience and this could more than double. HL whatever your strategy!

Interim Results September 2024

Jaywing plc (AIM: JWNG), the Data Science and Marketing business, with operations in the UK and Australia, today announces its interim results for the six months ended 30 September 2024 ("H1").

London South East

Look ahead to 2025; GreenRoc Strategic Minerals. Watch the interview here.

Share PricesJaywing Share PriceJaywing Share Regulatory NewsInterim Results

Pin to quick picksJaywing Regulatory News (JWNG)

JWNG Share Price

JWNG Share

Price

JWNG Share News

JWNG Share

News

JWNG Share Chat

JWNG Share

Chat

JWNG Share Trades

JWNG Share

Trades

6

JWNG Live RNS

JWNG

Live RNS

1

Jaywing Information

Buy JWNG Shares

Buy JWNG Shares

Add JWNG to Watchlist

Add JWNG to Watchlist

Add JWNG to Alert

Add JWNG to Alert

JWNG Live PriceLast checked at

09:46:06

Share Price Information for Jaywing (JWNG)

London Stock Exchange

Share Price:

1.60

Bid:

1.20

Ask:

2.00

Change:

0.25 (18.52%)

Spread: 0.80 (66.667%)Open: 1.25High: 1.60Low: 1.25Prev. Close: 1.35

Interim Results

Today 07:00

RNS Number : 6648Q

Jaywing PLC

19 December 2024

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation ("MAR") as applied in the United Kingdom. Upon publication of this Announcement, this information is now considered to be in the public domain.

19 December 2024

Jaywing plc

("Jaywing" or "the Company")

Interim Results September 2024

Jaywing plc (AIM: JWNG), the Data Science and Marketing business, with operations in the UK and Australia, today announces its interim results for the six months ended 30 September 2024 ("H1").

Financial highlights

6 months to

30 September 2024

6 months to

30 September 2023

Change

£'000

£'000

%

Revenue

9,452

11,107

(14.9%)

Adjusted EBITDA(1)

(88)

1,311

(106.7%)

Loss after tax for the period

(2,537)

(1,688)

Cash Generated from Operations

102

(123)

Net Debt (excluding IFRS 16) (2)

(14,770)

(11,925)

Reconciliation of Operating Profit/(Loss) with Adjusted EBITDA

6 months to

30 September 2024

£'000

6 months to

30 September 2023

£'000

Operating Loss

(1,363)

(537)

Add Back:

Depreciation

109

119

Depreciation of right of use assets

334

313

Amortisation of intangibles

232

227

EBITDA

(688)

122

Restructuring charges

604

1,189

Share based payment charge

(4)

-

Adjusted EBITDA(1)

(88)

1,311

Adjusted EBITDA margin

(0.9%)

11.8%

Contributions by Operating Unit

6 months to

30 September 2024

£'000

6 months to

30 September 2023

£'000

Change

%

Revenue

UK Agency

4,412

4,634

(4.8%)

UK Consulting

1,495

3,056

(51.0%)

Australia

3,545

3,417

Very good RNS!! L2 looking strong 📈

This will surely head back north soon. News not far away!!

Still !! COME ON ROCK, you can do it!!

19 December 2024

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Ultrafast CAR-T Manufacturing

Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in ultrafast CAR-T manufacturing technology, are pleased to announce a strategic collaboration to advance the production of CAR-T cell therapies for acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL).

This partnership aims to integrate Kure's ultrafast manufacturing (UM) technology with Hemogenyx Pharmaceuticals's proprietary CAR-T therapy, HG-CT-1 (formerly known as HEMO-CAR-T) to enable faster, more efficient production of CAR-T cells, significantly reducing manufacturing timelines while maintaining therapeutic potency.

Key Highlights of the Collaboration

1. Clinical Study: Hemogenyx Pharmaceuticals will initiate a clinical study to evaluate its CAR-T therapy for AML and KMT2A-rearranged ALL, utilizing Kure's UM process.

2. Process Development: Both parties will collaborate on developing a customized UM process for Hemogenyx Pharmaceutical's CAR-T therapy, optimizing its application in AML treatment.

3. Material and Expertise Sharing:Hemogenyx Pharmaceuticals will provide critical materials, including lentiviral vectors, and necessary technical know-how to facilitate process development.

4. In Vitro Testing:Hemogenyx Pharmaceuticals will conduct in vitro testing to assess the potency and vector copy number (VCN) of CAR-T cells manufactured using Kure's ultrafast platform.

5. Adaptation of Manufacturing Technology:Kure will adapt and refine its ultrafast CAR-T manufacturing process specifically to the Company's CAR-T therapy requirements.

6. Licensing Option: Upon successful completion of process development, Hemogenyx Pharmaceuticals will have the option to license Kure's UM technology for clinical trial production, with licensing terms to be negotiated.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "One of the most significant challenges in CAR-T therapy is the time and cost associated with manufacturing. Our partnership with Kure.ai allows us to explore and integrate a cutting-edge ultrafast manufacturing process that has the potential to revolutionize CAR-T production. This collaboration is an important step toward accelerating patient access to life-saving therapies."

Dr. David Wald, Founder of Kure.ai and Professor at Case Western Reserve University, added:"We are excited to partner with Hemogenyx Pharmaceuticals to adapt our ultrafast manufacturing platform to their innovative CAR-T therapy. This collaboration not only advances next-generation CAR-T solutions but also demonstrates the real-world clinical uti

Orosur Mining Inc - Share Placing

London, 19 December 2024. Orosur Mining Inc. ("Orosur" or the "Company") (TSX-V/AIM:OMI), announces that it has raised the sum of £1.25 million (before expenses) through a placing (the "Placing") of 18,939,394 new common shares of no par value ("Placing Shares" or "New Common Shares") at a price of 6.6 pence per Placing Share ("Placing Price"). Completion of the Placing is subject, amongst other things, to admission of the New Common Shares to trading on AIM ("Admission"), and review and acceptance by the TSX-V.

The Company held cash of US$500,000 (approximately £397,000) as at 18 December 2024, and the additional funds will be used largely to progress the Company's Anzá exploration project in Colombia. Work at Anzá will include further drilling at the Pepas prospect, mineral resource review work at APTA and more detailed sampling and mapping at El Cedro and El Roble.

Details of the Placing

The Placing Price represents a discount of approximately 25 per cent. to the closing mid-market price of the common shares on 18 December 2024, being the last trading day prior to the release of this announcement of the Placing, on both the AIM market and on the TSX-V.

The Placing Shares will, when issued, represent approximately 8.0 per cent of the existing common shares and will represent approximately 7.4 per cent. of the enlarged share capital of the Company.

The Placing was undertaken by Turner Pope Investments (TPI) Ltd ("Turner Pope" or "TPI"), the Company's Joint Broker.

Placing Agreement, Admission and Total Voting Rights

The Company and Turner Pope have entered into a placing agreement ("Placing Agreement") pursuant to which Turner Pope agreed to use its reasonable endeavours to procure placees pursuant to the Placing. The Placing Agreement contains certain warranties and indemnities given by the Company in favour of Turner Pope. It also contains provisions entitling Turner Pope to terminate the Placing Agreement prior to Admission if, among other things, a breach of any of the warranties occurs.

Completion of the Placing is subject, amongst other things, to the 18,939,394 New Common Shares being admitted to trading on AIM and is also conditional upon the Placing Agreement becoming unconditional in all respects and not being terminated in accordance with its terms. Application will be made for Admission. It is expected that Admission will become effective at 8.00am (GMT) on or around 30 December 2024.

Following the issue of the 18,939,394 New Common Shares, which on Admission will rank pari passu with the existing common shares, the total number of common shares in issue with voting rights in the Company will be 255,459,097.

The above figure of 255,459,097 common shares may therefore be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company und

$xtp Locking Feature in UK 🇬🇧 is back

What's next:

LATAM 🔥

Cross border payments

Multicurrency support

Stock trading & lending

Savings account

Salary deposits

With $xtp utility in every new feature, and compliance becoming more crypto friendly

100x 💎

📉 Market Movements:

• Following #Powell's hawkish remarks, #Bitcoin dropped below $100,000, declining by 5% within 24 hours. numerous #altcoins experienced losses exceeding 10%.

• total market #liquidations amounted to $709 million, with $612 million resulting from the liquidation of long positions.

• On December 18th, Bitcoin spot #ETFs saw a total net inflow of $275 million.

• On December 18th, #Ethereum spot ETFs had a total net inflow of $24.513 million.

• Total #trading volume on #NFT marketplaces reached $117 million, marking the highest level since February 23, 2023.

🏦 Regions and Policies:

• The #Federal Reserve announced the interest rate ceiling at 4.50%, in line with expectations and down from the previous 4.75%.

• The Bank of #Japan announced it will maintain the uncollateralized overnight call rate, which serves as the policy rate, at 0.25%.

• #ElSalvador reached a $1.4 billion loan agreement with the #IMF, with Bitcoin acceptance becoming voluntary.

• #Europol seized $26 million in #cryptocurrency from nine drug traffickers.

💼 Institutional and industry information:

• #Marathon Digital acquired 1,627 BTC in the past 8 hours, valued at approximately $166 million.

• #MicroStrategy plans to pivot towards fixed-income securities to raise funds for purchasing Bitcoin.

• The #Trump family's crypto project, World Liberty, acquired an additional 231,726 $ENA tokens.

• #Coinbase has been approved to delist $WBTC, as the judge dismissed #BiT Global's appeal.

• Arthur #Hayes suggests that #Trump's team might bypass the #Fed to "print money."

- BTC

📉 24h Change: -2.55%

⬆️ 24h High: 105306 USDT

⬇️ 24h Low: 98840 USDT

- ETH

📉 24h Change: -4.57%

⬆️ 24h High: 3894.84 USDT

⬇️ 24h Low: 3564.24 USDT

💡 Market Sentiment

Fear and Greed Index falls back to 75

#CryptoNews #cryptomarket #BTC #ETH

#Crypto New’s: 🇭🇰 The Hong Kong SFC has just approved four new #Bitcoin and #crypto exchanges! 🇭🇰China is getting ready for the 2025 🐮 🏃‍♂️

Question put to #TAP via X

Hai @Tap_Fintech is there any change to expand in to Asia .. would be bullish if the Chinese started staking $xtp next

I'll take that, given recent weeks trading. And mostly blue!!!

Well done SG 👏

Vol. Sold 1,782,994

Sold Value £157.93k

Vol. Bought 2,250,321

Bought Value £194.77k

A good day!

Vol. Sold 2,654,066

Sold Value £1.36m

Vol. Bought 2,904,857

Bought Value £1.48m

Think we might also see a good few buys, remaining 10 minutes. We'll see....